Loading...
Market
What will be the new annual price tier for lenacapavir announced by Gilead Sciences by end of 2024?
2
Resolution / Starting Odds
Less than $50 annually • 25%
$50 to $100 annually • 25%
$100 to $500 annually • 25%
More than $500 annually • 25%
Official press release from Gilead Sciences or reputable news sources
Story
Gilead HIV Treatment Could Be Made for $26 to $40 Annually, 1,000 Times Cheaper
Jul 23, 2024, 01:25 PM
A new analysis reveals that a Gilead Sciences HIV treatment, lenacapavir, could be produced for as little as $26 to $40 per person each year, significantly lower than its current price of over $40,000. Researchers highlight that this 'vaccine-like' drug has the potential to both prevent and suppress HIV, offering a groundbreaking advancement in HIV treatment. The cost reduction, which equates to approximately Ksh. 5280 and makes the treatment 1,000 times cheaper, could make the treatment accessible to a broader population, potentially revolutionizing HIV care globally.
View original story
Similar markets
Uniform pricing across all markets • 25%
Tiered pricing based on market income levels • 25%
Significant discounts in low-income countries • 25%
Other pricing strategy • 25%
Below $10,000 per year • 25%
$10,000 - $20,000 per year • 25%
$20,000 - $30,000 per year • 25%
Above $30,000 per year • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Global Fund • 25%
PEPFAR • 25%
Gilead Sciences • 25%
Other • 25%
Cost • 25%
Distribution • 25%
Regulatory approval • 25%
Adherence • 25%
Approved in USA only • 25%
Approved in EU only • 25%
Approved in both USA and EU • 25%
Not approved in USA or EU • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%